EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Scope & Guideline

Pioneering Insights for the Future of Pharmacology.

Introduction

Immerse yourself in the scholarly insights of EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageMulti-Language
ISSN0223-5234
PublisherELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
Support Open AccessNo
CountryFrance
TypeJournal
Convergefrom 1974 to 2024
AbbreviationEUR J MED CHEM / Eur. J. Med. Chem.
Frequency18 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE

Aims and Scopes

The European Journal of Medicinal Chemistry focuses on the synthesis, evaluation, and development of novel compounds with therapeutic potential. It encompasses a wide range of medicinal chemistry topics, including drug design, structure-activity relationships, and the exploration of new therapeutic targets. The journal emphasizes innovative approaches in drug discovery, particularly those that integrate computational methods with experimental validation.
  1. Drug Design and Discovery:
    The journal publishes research on the design and synthesis of new drug candidates, highlighting innovative strategies for targeting various diseases, including cancer, infectious diseases, and metabolic disorders.
  2. Structure-Activity Relationship (SAR) Studies:
    A significant focus is placed on SAR studies, which investigate the relationship between chemical structure and biological activity to optimize the efficacy and selectivity of drug candidates.
  3. Targeted Protein Degradation:
    The journal features studies on PROTACs (proteolysis-targeting chimeras) and other modalities that aim to induce targeted degradation of specific proteins, offering a novel approach to cancer therapy and beyond.
  4. Nanotechnology in Drug Delivery:
    Research on nanotechnology applications in enhancing drug delivery systems, improving bioavailability, and targeting specific tissues or cells is a prominent theme.
  5. Natural Products and Derivatives:
    The journal explores the medicinal properties of natural products and their synthetic derivatives, investigating their potential as therapeutic agents and the mechanisms of action involved.
  6. Multitarget Approaches:
    There is a growing emphasis on the development of multitarget drugs that can simultaneously interact with multiple biological pathways, enhancing therapeutic efficacy and reducing resistance.
  7. Computational Chemistry:
    The integration of computational methods for predicting interactions, optimizing lead compounds, and informing synthetic strategies is a key component of the research published in the journal.
The European Journal of Medicinal Chemistry has seen a shift towards several trending and emerging themes that reflect current challenges and advances in the field of medicinal chemistry. These areas highlight the journal's commitment to addressing contemporary health issues through innovative research.
  1. Targeted Protein Degradation Technologies:
    The rise of PROTACs and other targeted degradation technologies is a significant trend, with increasing numbers of papers focusing on the design and application of degraders for therapeutic purposes.
  2. Immunotherapy and Immune Modulation:
    There is an emerging focus on small molecules that modulate immune responses, particularly in the context of cancer therapy, highlighting the intersection of medicinal chemistry and immunology.
  3. Artificial Intelligence in Drug Discovery:
    The integration of artificial intelligence and machine learning in drug discovery processes is gaining traction, with research exploring how these technologies can accelerate the identification of lead compounds.
  4. Nanomedicine and Drug Delivery Systems:
    Research that emphasizes the development of nanotechnology-based drug delivery systems is on the rise, focusing on improving the delivery and efficacy of therapeutics while minimizing side effects.
  5. Multifunctional Therapeutics:
    Emerging interest in multifunctional drugs that target multiple pathways or mechanisms simultaneously is evident, reflecting a shift towards more comprehensive therapeutic strategies.
  6. Natural Product Derivatives with Enhanced Activities:
    The exploration of derivatives of natural products, particularly those with optimized pharmacological profiles, is increasingly common as researchers seek to harness the therapeutic potential of these compounds.
  7. Research on Metabolic Disorders:
    A growing number of studies are addressing metabolic disorders, including diabetes and obesity, with a focus on discovering new therapeutic agents that can effectively manage these conditions.

Declining or Waning

While the journal covers a broad spectrum of medicinal chemistry topics, certain themes appear to be experiencing a decline in focus. This may reflect shifting interests in the field or emerging methodologies that supersede older approaches.
  1. Traditional Small Molecule Inhibitors:
    Research focusing solely on traditional small molecule inhibitors without integrating newer methodologies, such as PROTACs or nanotechnology, seems to be less frequent as the field evolves towards more innovative therapeutic approaches.
  2. Single Target Drug Development:
    There is a noticeable decline in publications centered around single-target drug development. The trend is shifting towards multitarget strategies that address the complexity of diseases, particularly in cancer and chronic conditions.
  3. Synthetic Pathway Optimization:
    Publications dedicated exclusively to optimizing synthetic pathways without a strong emphasis on biological evaluation are becoming less common, as researchers increasingly prioritize bioactivity and therapeutic relevance in their studies.
  4. Basic Pharmacology Studies:
    Basic pharmacological studies that do not explore clinical implications or translational potential are appearing less frequently, reflecting a growing expectation for research to connect laboratory findings with clinical applications.

Similar Journals

ARCHIV DER PHARMAZIE

Advancing Pharmaceutical Science and Drug Discovery
Publisher: WILEY-V C H VERLAG GMBHISSN: 0365-6233Frequency: 12 issues/year

ARCHIV DER PHARMAZIE is a prestigious journal published by WILEY-V C H VERLAG GMBH, dedicated to pioneering advances in the fields of Pharmaceutical Science and Drug Discovery. With an impactful history dating back to its inception in 1822, this journal is recognized for its significant contribution to the pharmaceutical sciences, maintaining an impressive Q2 ranking in both the Drug Discovery and Pharmaceutical Science categories as of 2023. The journal’s commitment to excellence is reflected in its Scopus rankings, placing it in the top tiers of relevant fields, ensuring a broad reach and impact among researchers and professionals. Although Open Access options are not available, ARCHIV DER PHARMAZIE continues to be an invaluable resource for scholars seeking to stay abreast of cutting-edge research and developments in pharmacy and related sciences. The journal’s contributions not only serve as crucial benchmarks in research but also enhance the understanding of pharmaceutical innovations, making it essential reading for both seasoned professionals and students alike.

CURRENT MEDICINAL CHEMISTRY

Catalyzing Breakthroughs in Health Sciences.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 0929-8673Frequency: 42 issues/year

Current Medicinal Chemistry is a leading journal published by Bentham Science Publishers Ltd, known for its rigorous focus on the multifaceted realm of medicinal chemistry. With an ISSN of 0929-8673 and E-ISSN 1875-533X, the journal plays a crucial role in disseminating high-quality research findings that bridge the gap between chemistry and health sciences. Operating from Sharjah, United Arab Emirates, it has been a prominent scholarly resource since its inception in 1994, and is expected to continue until 2024. Current Medicinal Chemistry has earned its place in the academic community with an impressive impact factor and categorization in Q1 and Q2 quartiles across various disciplines, including Organic Chemistry, Biochemistry, Drug Discovery, and Pharmacology, highlighting its substantial contribution to these fields. Notably, it ranks 24th in Organic Chemistry and is within the 88th percentile, underscoring its appeal to researchers, professionals, and students alike who are keen on exploring cutting-edge advancements in drug design and development. Although it is not an open-access journal, it provides vital content that informs and inspires innovation in medicinal chemistry, appealing to a global audience committed to enhancing human health through scientific discovery.

Acta Pharmaceutica Sinica B

Connecting Researchers for Groundbreaking Discoveries
Publisher: INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCESISSN: 2211-3835Frequency: 6 issues/year

Acta Pharmaceutica Sinica B is a prestigious open access journal that has been setting the standard in the field of pharmacology, toxicology, and pharmaceutics since its establishment in 2011. Published by the Institute of Materia Medica, Chinese Academy of Medical Sciences, the journal serves as a vital platform for researchers, professionals, and students seeking to disseminate innovative findings in drug development, pharmaceutical sciences, and therapeutic applications. With an impressive impact factor reflecting its high academic quality, Acta Pharmaceutica Sinica B has achieved Q1 status in the category of Pharmacology, Toxicology and Pharmaceutics as of 2023, ranking #1 out of 80 journals in General Pharmacology. This journal not only focuses on the latest advancements in drug research and formulation but also emphasizes interdisciplinary approaches, fostering collaborations that span various scientific domains. The accessible nature of the journal, combined with its rigorous peer-review process, ensures that crucial insights and breakthroughs reach a global audience swiftly and effectively. For those looking to stay at the forefront of pharmaceutical research, Acta Pharmaceutica Sinica B is an indispensable resource.

ACS Medicinal Chemistry Letters

Fostering collaboration in the quest for medicinal excellence.
Publisher: AMER CHEMICAL SOCISSN: 1948-5875Frequency: 12 issues/year

ACS Medicinal Chemistry Letters, published by the American Chemical Society, is a distinguished journal dedicated to advancing the field of medicinal chemistry. With impressive rankings in the 2023 category quartiles—Q1 in Drug Discovery and Organic Chemistry as well as Q2 in Biochemistry—this journal serves as a vital platform for researchers seeking to publish innovative findings and methodologies in drug development and therapeutic advancements. The journal's notable impact is reflected in its Scopus rankings, where it stands at #43 in Organic Chemistry and #45 in Drug Discovery. Although it does not currently offer open access, the contributions published from 2010 to 2024 provide a wealth of knowledge critical to both academia and industry. As a key resource for students, professionals, and researchers in the fields of chemistry and pharmacology, ACS Medicinal Chemistry Letters plays an essential role in shaping the future of medicinal therapeutics.

CURRENT TOPICS IN MEDICINAL CHEMISTRY

Pioneering Research for Tomorrow's Medicines
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1568-0266Frequency: 32 issues/year

CURRENT TOPICS IN MEDICINAL CHEMISTRY is a prestigious journal published by Bentham Science Publishers Ltd, dedicated to advancing the field of medicinal chemistry through the dissemination of high-quality research from 2001 to 2024. With an ISSN of 1568-0266 and an E-ISSN of 1873-4294, this journal is recognized for its significant contributions, as evidenced by its Scopus ranking in the 63rd percentile in the category of Drug Discovery, specifically at position #58 out of 157. Currently placed in Quartile 3 within Drug Discovery and Quartile 2 in miscellaneous medicine as of 2023, it serves as an essential resource for researchers, professionals, and students interested in the latest developments, methodologies, and applications in medicinal chemistry. The journal aims to foster collaboration and innovation by featuring original research articles, reviews, and brief communications that address current and emerging challenges in the discipline. Although it is not an open access platform, the journal's rich content is indispensable for those striving to enhance therapeutic strategies and drug development processes.

Journal of Natural Medicines

Exploring the Frontiers of Natural Therapeutics
Publisher: SPRINGER JAPAN KKISSN: 1340-3443Frequency: 4 issues/year

Journal of Natural Medicines, published by SPRINGER JAPAN KK, is a leading academic journal that plays a pivotal role in the advancement of research in the fields of Complementary and Alternative Medicine, Drug Discovery, Molecular Medicine, Organic Chemistry, and Pharmaceutical Science. Established in 1994 and set to continue until 2024, this journal serves as a vital conduit for the dissemination of groundbreaking research and innovative ideas that bridge traditional medicinal knowledge and modern scientific inquiry. With its impressive ranking in Scopus—ranking #12 out of 105 in Complementary and Alternative Medicine and holding a Q1 category quartile for 2023—it stands as a reputable source for high-quality, peer-reviewed articles. The journal's commitment to excellence is further underscored by its inclusion in the Springer network, providing researchers, professionals, and students with valuable insights and the latest developments in natural medicines. Although this journal operates under a subscription model, its profound impact on these interdisciplinary fields makes it an essential resource for anyone engaged in the study or practice of natural medicinal therapies.

MOLECULAR DIVERSITY

Unveiling Innovations in Molecular Diversity
Publisher: SPRINGERISSN: 1381-1991Frequency: 4 issues/year

MOLECULAR DIVERSITY, published by Springer, stands as a pivotal platform within the fields of chemistry, biology, and pharmacology since its inception in 1995. This esteemed journal aims to foster interdisciplinary research and innovation, particularly in areas such as catalysis, drug discovery, inorganic and organic chemistry, and molecular biology. With a diverse scope that reflects contemporary scientific challenges, it has been recognized for its significant contributions, boasting commendable Scopus rankings and an impact factor that underscores its relevance in critical fields. Although not an open access journal, MOLECULAR DIVERSITY continues to influence and engage researchers, professionals, and students alike by providing a forum for high-quality peer-reviewed articles and cutting-edge research findings. As it converges years of scientific dynamism from 1995 to 2024, this journal remains vital for those advancing the frontiers of molecular science and engineering.

PHARMACEUTICAL CHEMISTRY JOURNAL

Advancing Drug Discovery Through Scholarly Excellence.
Publisher: SPRINGERISSN: 0091-150XFrequency: 12 issues/year

Pharmaceutical Chemistry Journal is a pivotal publication in the field of pharmaceutical sciences, renowned for its in-depth articles and research findings. Published by Springer in the United States, this journal provides a crucial platform for researchers, students, and professionals dedicated to advancing drug discovery and pharmacology. With an ISSN of 0091-150X and an E-ISSN of 1573-9031, this journal has consistently aimed to promote scholarly communication and innovation within its scope since its inception in 1967. Despite its current Category Quartiles ranking of Q4 in both Drug Discovery and Pharmacology, the journal remains a valuable resource for disseminating new ideas and findings that contribute to the scientific community. Researchers benefit from the journal's commitment to high-quality peer-reviewed content, even in an environment where open access options are currently not available. As the field evolves, the Pharmaceutical Chemistry Journal continues to play an important role in shaping future advancements in drug development and safety.

Heterocyclic Letters

Fostering Excellence in Heterocyclic Compound Studies
Publisher: RAMAN PUBLISSN: 2231-3087Frequency: 4 issues/year

Heterocyclic Letters is an esteemed journal in the field of synthetic organic chemistry, published by RAMAN PUBL. With ISSN 2231-3087 and E-ISSN 2230-9632, this journal aims to disseminate original research and innovative findings related to heterocyclic compounds, which play a crucial role in medicinal chemistry, material science, and agricultural chemistry. Heterocyclic Letters provides a platform for researchers, professionals, and students to share their insights and advancements, thus fostering academic collaboration and knowledge transfer. The journal is dedicated to maintaining high-quality standards in research publication, making it an essential resource for anyone focused on the latest developments in heterocyclic chemistry. Although it does not currently offer Open Access options, the journal’s rigorous peer-review process ensures that only the most credible and impactful studies are published, contributing significantly to the advancement of the field.

JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

Transforming Discoveries into Therapeutic Solutions
Publisher: TAYLOR & FRANCIS LTDISSN: 1475-6366Frequency: 1 issue/year

JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, published by Taylor & Francis Ltd, is a premier open-access journal that has been at the forefront of research in the field of medicinal chemistry since its inception in 1985. With an ISSN of 1475-6366 and an E-ISSN of 1475-6374, this journal boasts a prestigious reputation reflected in its impressive Q1 rankings across critical categories such as Drug Discovery and Pharmacology as of 2023. Situated in the United Kingdom, it plays a vital role in disseminating high-quality research that addresses the burgeoning needs of drug discovery and enzyme inhibition methodologies. The journal supports full open access, providing a platform for researchers, professionals, and students to share significant findings and innovations widely. With a robust impact factor, the JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY is indispensable for any academic or professional involved in the pharmacological sciences, offering an unparalleled insight into the latest advancements in therapeutic strategies and drug development.